250,468 Shares in Roivant Sciences Ltd. $ROIV Acquired by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC acquired a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 250,468 shares of the company’s stock, valued at approximately $5,435,000.

Several other large investors also recently added to or reduced their stakes in ROIV. Bessemer Group Inc. boosted its holdings in shares of Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares in the last quarter. Allworth Financial LP grew its stake in shares of Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the last quarter. Utah Retirement Systems grew its stake in shares of Roivant Sciences by 3.0% in the third quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock worth $312,000 after purchasing an additional 600 shares during the last quarter. Xponance Inc. increased its holdings in Roivant Sciences by 1.9% during the 3rd quarter. Xponance Inc. now owns 46,718 shares of the company’s stock valued at $707,000 after purchasing an additional 882 shares during the period. Finally, Oregon Public Employees Retirement Fund increased its holdings in Roivant Sciences by 1.2% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 86,652 shares of the company’s stock valued at $1,311,000 after purchasing an additional 1,019 shares during the period. Institutional investors own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

ROIV has been the subject of several research analyst reports. Leerink Partners increased their price objective on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Guggenheim upped their target price on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a report on Monday, February 9th. Sanford C. Bernstein started coverage on shares of Roivant Sciences in a report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price target on the stock. The Goldman Sachs Group boosted their price objective on shares of Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, Citigroup upped their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

Insider Buying and Selling

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $26.49, for a total value of $5,298,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,654,597 shares of the company’s stock, valued at approximately $43,830,274.53. The trade was a 10.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Frank Torti sold 1,400,000 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $27.42, for a total transaction of $38,388,000.00. Following the completion of the transaction, the insider owned 13,736,547 shares in the company, valued at approximately $376,656,118.74. This represents a 9.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 5,801,081 shares of company stock valued at $150,970,445 over the last ninety days. Insiders own 10.80% of the company’s stock.

Roivant Sciences Stock Down 0.4%

Roivant Sciences stock opened at $26.41 on Tuesday. The stock’s 50 day moving average is $26.39 and its 200 day moving average is $21.89. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $30.33. The company has a market capitalization of $18.90 billion, a P/E ratio of -22.57 and a beta of 1.17.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.